Prescribing information

 

This site contains information for healthcare professionals on Xolair for severe allergic asthma.

___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Xolair should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma.1

Adults and adolescents (12 years of age and older)

Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.1

Children (6 to <12 years of age)

Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.1

 

 

*Xolair provides clinically meaningful improvements in quality of life for patients with severe allergic asthma.2

FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; SAA, severe allergic asthma.

References

  1. Xolair® (omalizumab) Summary of Product Characteristics.
  2. Braunstahl GJ et al. Resp Med 2013;107(8):1141–1151.
XSA20-C011 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]